Zachary Brecheisen Bio

Zachary Brecheisen is a corporate lawyer focusing his practice on mergers and acquisitions and other strategic transactions. He counsels clients on a variety of corporate governance matters, including activist investor campaigns. Zach places a premium on efficiency in providing clients with forthright and practical legal advice in high-pressure situations. He taps his background as an engineer to manage cross-functional teams on complex issues, all while driving transactions forward and achieving client goals. Zach is recognized by Chambers USA and praised by clients for his "extreme efficiency" and ability to "keep it concise." Zach advises clients across a broad range of industries. Recently he represented Evoqua (NYSE: AQUA) in its $7.5 billion sale to Xylem, Cibus Global (Nasdaq: CBUS) in its reverse merger with Calyxt, and Misonix (Nasdaq: MSON) in its $520 million sale to Bioventus. He has represented Ansys (Nasdaq: ANSS) in numerous acquisitions (including its $700 million acquisition of AGI). Zach advised midwestern stalwarts like Wabtec (NYSE: WAB) in its $1.8 billion acquisition of Evident's testing/measurements business and U. S. Steel (NYSE: X) in its $640 million sale of Transtar and its option agreement with Stelco for a potential $2.4 billion joint venture. Prior to law school, Zach was a project engineer advising electric utilities on transmission and distribution system planning and arc-hazard protection. Zach is co-chair of the Firm's LGBTQ+ Affinity Group and has been honored by Penn State University and The Legal Intelligencer for his contributions to the law school and dedication to diversity and inclusion in the profession.